Phase 4Active, not recruiting

Statin Combined With Amlodipine Treats Primary Aldosteronism (STOP-PA)

A Prospective, Multi-center, Randomized Trial to Compare Statin Combined With CCB to MRA Combined With CCB in Primary Aldosteronism Treatment

Sponsor
Third Military Medical University (Academic or other)
Enrollment
180 planned
Conditions
Primary Aldosteronism; Statin; Mineralocorticoid Receptor Antagonist; Hypertension
Interventions
Simvastatin combined with Amlodipine besylate; Simvastatin combined with Spironolactone and Amlodipine besylate.; Amlodipine besylate combined Spironolactone
Ages
adults, older adults
Registry
NCT06523465

Full record on ClinicalTrials.gov

From the registry

The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.

Primary outcomes

  • changes in plasma aldosterone levels

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered